We are live on
!
Find out more
CC
Colrain Capital Portfolio holdings
AUM
$259M
1-Year Est. Return
63.6%
This Fund
S&P 500
This Quarter
Est. Return
+9.16%
1 Year Est. Return
+63.6%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$85.3M
AUM Growth
+$8.27M
(+11%)
Cap. Flow
+$2.82M
Cap. Flow
% of AUM
3.31%
Top 10 Holdings %
Top 10 Hldgs %
56.78%
Holding
49
New
6
Increased
6
Reduced
23
Closed
1
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Cigna
CI
|
+$2.33M |
| 2 |
HES
Hess
HES
|
+$1.18M |
| 3 |
CVS Health
CVS
|
+$1.09M |
| 4 |
Apple
AAPL
|
+$373K |
| 5 |
Vanguard Dividend Appreciation ETF
VIG
|
+$306K |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Gilead Sciences
GILD
|
+$1.29M |
| 2 |
AGN
Allergan plc
AGN
|
+$650K |
| 3 |
International Paper
IP
|
+$283K |
| 4 |
Comcast
CMCSA
|
+$251K |
| 5 |
The Mosaic Company
MOS
|
+$250K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 19.75% |
| 2 | Healthcare | 19.57% |
| 3 | Communication Services | 11.87% |
| 4 | Materials | 9.81% |
| 5 | Financials | 8.58% |
Similar funds
NAM
CCAM
QP
BFA
PW
BFP
TC
FC
Colrain Capital's Q1 2019 Portfolio in Review
As of Q1 2019, Colrain Capital held 49 positions worth $85.3M, up 11% from $77M the previous quarter. Its ten largest holdings account for 57% of the portfolio.
Colrain Capital deployed $2.82M of net new capital in Q1 2019, opening 6 new positions and adding to 6 existing holdings. Its largest new stake was Vanguard Dividend Appreciation ETF: 2,900 shares worth $318K.
By sector, the portfolio is most concentrated in Technology at 20% of assets, up from 19% a quarter earlier, followed by Healthcare and Communication Services.
On the sell side, the largest reduction was Allergan plc, an estimated $650K trimmed.
- Colrain Capital's largest Q1 2019 buy was Vanguard Dividend Appreciation ETF: 2,900 shares worth $318K.
- Colrain Capital added most to Cigna in Q1 2019, an estimated $2.33M increase.
- Colrain Capital's biggest Q1 2019 reduction was Allergan plc, cutting an estimated $650K.
- Colrain Capital fully exited Gilead Sciences in Q1 2019, selling an estimated $1.29M.
- Colrain Capital's ten largest holdings make up 57% of its $85.3M portfolio in Q1 2019.
- Colrain Capital opened 6 new positions and closed 1 in Q1 2019.
- Colrain Capital's portfolio value rose 11% quarter-over-quarter to $85.3M.
Based on Colrain Capital's 13F filing for Q1 2019, filed 2 May 2019.